From the Nasdaq MarketSite studio, Dr. Seth Lederman, MD, CEO of Tonix Pharmaceuticals, Inc. (NASDAQ: TNXP) ($TNXP) (“Tonix”), talks with New to The Street’s TV Host Jane King. As a clinical-stage biopharmaceutical Company, Tonix Pharmaceuticals, Inc. aims to improve health through the innovation of vaccines and therapies. Seth explains that current monoclonal antibody treatments used against COVID-19 no longer work and are no longer available in the market. The new COVID variants rendered those antibody treatments useless against the virus. In December 2022, Tonix entered into a license agreement with Curia Global, Inc. to develop three (3) humanized murine monoclonal antibodies for the treatment and prevention of COVID. Monoclonal antibody treatments are usually for patients who are very old, with medical comorbidities, and with compromised immune systems. Seth looks to help organ transplant recipients with compromised immune systems with a treatment. These patients get sick very quickly. Currently, Tonix is in the developmental stage of the monoclonal antibodies, and once FDA-approved, many patients can benefit. Seth tells viewers that the shareholder value proposition looks strong. And recently, a large institutional buyer became a large shareholder in TNXP. The on-screen QR code is available during the show; download or visit Tonix Pharmaceuticals, Inc. – https://www.tonixpharma.com/.
To make sure you never miss a video from New to the Street, click here to subscribe: https://www.youtube.com/c/newtothestreettv
Follow New to the Street on Twitter: https://twitter.com/NewToTheStreet
Follow New to the Street on Facebook: https://www.facebook.com/newtothestreet/
Follow New to the Street on Instagram: https://www.instagram.com/newtothestreettv/
Follow New to the Street on Rumble: https://rumble.com/user/newtothestreet
About New to the Street: https://newtothestreet.com/
Subscribe to our Mailing List: https://mailchi.mp/ccd21b3e3fab/join-our-mailing-list